©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2024; 30(44): 4759-4762
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4759
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4759
Role of Helicobacter pylori in esophageal carcinogenesis: Friend or foe?
Cong Zhang, Yong-Wen Ouyang, Zhao-Tao Li, Department of Gastroenterology, The First People’s Hospital of Foshan, Foshan 528000, Guangdong Province, China
Co-first authors: Cong Zhang and Yong-Wen Ouyang.
Co-corresponding authors: Cong Zhang and Zhao-Tao Li.
Author contributions: Zhang C and Ouyang YW designed the manuscript outline and contributed to writing the manuscript; Zhang C and Li ZT designed the overall concept of the manuscript and revised the draft; All the authors have read and approved the final manuscript.
Supported by the Guangdong Basic and Applied Basic Research Foundation , No. 2023A1515140118 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Cong Zhang, MD, PhD, Doctor, Department of Gastroenterology, The First People’s Hospital of Foshan, No. 81 Lingnan Avenue North, Foshan 528000, Guangdong Province, China. zhangc57@mail2.sysu.edu.cn
Received: August 10, 2024
Revised: September 22, 2024
Accepted: October 22, 2024
Published online: November 28, 2024
Processing time: 93 Days and 17.6 Hours
Revised: September 22, 2024
Accepted: October 22, 2024
Published online: November 28, 2024
Processing time: 93 Days and 17.6 Hours
Core Tip
Core Tip: López-Gómez et al provided evidence of a very low prevalence of previous Helicobacter pylori infection in a Spanish cohort of patients with esophageal carcinoma, and most of those patients had previously received or concomitantly received proton pump inhibitors treatment. However, more studies (such as prospective studies or Mendelian randomization studies) are still needed to confirm the causal relationship between them in the future.